Panitumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Epidermal growth factor receptor (EGFR) |
| Clinical data | |
| Trade names | Vectibix |
| Other names | ABX-EGF |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607066 |
| License data |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | ~9.4 days (range: 4-11 days) |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C6398H9878N1694O2016S48 |
| Molar mass | 144324.12 g·mol−1 |
| (what is this?) (verify) | |
Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Panitumumab is manufactured by Amgen and was originally developed by Abgenix Inc.
In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany panitumumab.